Investigational drug · Phase 3
PF614
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Postoperative Pain, Acute.
Phase 3Last checked: Nov 19, 2026Latest source record: Jan 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
8
Any phase or sponsor naming "PF614"
First trial start
2025
Dec 9, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PF614", any sponsor or status.
Conditions studied
As listed on its trial records.
- Postoperative Pain, Acute
Approved drugs for the same conditions: Pain and anesthesia
Largest trials
Live from ClinicalTrials.gov: studies naming "PF614" as an intervention, largest first.
- PF614 Analgesic Activity in Acute Postoperative Pain (PF614-301)Pivotal-lookingRecruiting
Ensysce BiosciencesIndustry
NCT06602271 · 320 participants (planned) · Start Dec 9, 2025 · Primary completion Aug 2026
Drug: PF614 capsule; Placebo · For: Postoperative Pain, Acute
Sites: Atlanta, Georgia; Houston, Texas; Salt Lake City, Utah
- Pharmacokinetics of Oxycodone and PF614 Co-Administered with Nafamostat (PF614-MPAR-101)Pivotal-lookingCompleted
Ensysce BiosciencesIndustry
NCT05090280 · 111 participants · Start Dec 1, 2021 · Primary completion Apr 26, 2023
Drug: PF614 solution; Naltrexone Hydrochloride and 1 more · For: Pharmacokinetics
Sites: Miami, Florida
Ensysce BiosciencesIndustry
NCT05043766 · 84 participants · Start Sep 8, 2021 · Primary completion Mar 21, 2022
Drug: PF614; Naltrexone Hydrochloride and 1 more · For: Healthy Volunteers
Sites: Salt Lake City, Utah
Ensysce BiosciencesIndustry
NCT02454712 · 64 participants · Start Nov 16, 2016 · Primary completion Jan 18, 2018
Drug: PF614; Oxycodone extended-release and 1 more · For: Healthy
Sites: Lenexa, Kansas
Ensysce BiosciencesIndustry
NCT06500793 · 54 participants (planned) · Start Nov 24, 2024 · Primary completion Dec 22, 2026
Drug: PF614 capsule; Nafamostat Mesylate · For: Pharmacokinetics; Healthy Volunteer
Sites: Miami, Florida
Ensysce BiosciencesIndustry
NCT05571345 · 32 participants · Start Oct 5, 2022 · Primary completion Dec 23, 2022
Drug: PF614; Oxycodone Hydrochloride 40 mg and 1 more · For: Recreational Drug Use
Sites: Overland Park, Kansas
Ensysce BiosciencesIndustry
NCT05567354 · 27 participants · Start Jun 10, 2022 · Primary completion Aug 31, 2022
Drug: PF614; Oxycodone · For: Recreational Drug Use
Sites: Columbus, Ohio
Ensysce BiosciencesIndustry
NCT06629402 · 16 participants · Start Oct 5, 2023 · Primary completion Nov 14, 2023
Drug: PF614; Placebo · For: Acute Pain
Sites: Overland Park, Kansas
Newest research
PubMed records naming it or its code names, newest first.
- Formulation development and a Phase 1 clinical study of PF614-MPAR, an oxycodone prodrug with oral opioid overdose protection.
Kirkpatrick DL, Pestano LA, Evans C, et al. · J Opioid Manag 2026
- Polyhedral {Ag12} and {Ag16} Clusters: Synthesis, Structural Characterization and Third-Order Nonlinear Optical Properties.
Xie HP, Jin XH, Li JY, et al. · Chem Asian J 2024
- Clinical evaluation of PF614, a novel TAAP prodrug of oxycodone, versus OxyContin in a multi-ascending dose study with a bioequivalence arm in healthy volunteers.
Kirkpatrick DL, Evans C, Pestano LA, et al. · Clin Transl Sci 2024
- Nonclinical safety assessment of PF614: A novel TAAP prodrug of oxycodone for chronic pain indication.
Joshi PS, Sanakkayala N, Kirkpatrick L, et al. · Regul Toxicol Pharmacol 2019
- In vitro and in vivo assessment of the abuse potential of PF614, a novel BIO-MDࡊ prodrug of oxycodone.
Kirkpatrick DL, Schmidt WK, Morales R, et al. · J Opioid Manag 2017
- Stepwise assembly of an adamantoid RuࠤAgࠦ cage by control of metal coordination geometry at specific sites.
Metherell AJ, Ward MD · Chem Commun (Camb) 2014
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.